Back to all Companies

Advantis Medical Imaging

Visit Website
Healthcare & Life SciencesEnterprise Medical Software and Services
Year Founded
Year Selected
Eindhoven, Netherlands
Team Size


A pioneering manufacturer of cloud-based medical imaging software solutions.

Advantis Medical Imaging, founded in 2016 by Paris Ziogkas, Zoi Giavri and Dimitris Rozakis, is looking to revolutionize medical imaging analysis with the help of AI and cloud technology. Their mission and vision is to simplify and optimize imaging processes, ultimately making them more accessible. The co-founders are dedicated to developing solutions that provide real benefit to clinical organizations by reducing their workload and allowing them to focus on their patients. By automating the imaging process, clinicians can spend more time analyzing clinical findings and coming up with personalized treatment plans. Advantis' flagship product, Brainance MD, is an advanced neuroimaging platform that has been both FDA cleared and CE Marked. It is designed to display and process multiple brain MRI sequences in a highly intuitive user interface, provided as a Software as a Service (SaaS). The product is just the first step in the company's plan to offer a comprehensive and automated imaging suite that covers a wide range of medical image processing needs and pathologies. In 2023, the company also launched its prostate solution, shortly after receiving its second FDA approval. Advantis Medical Imaging is taking a bold step towards streamlining medical imaging analysis and bringing it into the 21st century.


Advantis Medical Imaging has developed a pioneering approach to revolutionizing medical imaging analysis with a commitment to simplifying and optimizing imaging processes. They have been twice FDA cleared and CE Marked for their brain and prostate solutions. The company recently won first prize at the Pfizer CDI Start4Health program.


investor logo
ScaleUp Program

Relevant Resources

See All

Endeavor Welcomes 17 New Companies to the ScaleUp Program with the Launch of its 3rd Batch

Jul 7, 2021